Odyssey Thera compounding profiling service

Wednesday, 20 April, 2011 | Supplied by: Lonza Australia Pty Ltd

Using cutting-edge Protein-fragment Complementation Assay technology from Odyssey Thera, Lonza is able to offer profiling services that can shape and influence critical decisions about drug candidates.

This unique cell-wide analysis platform broadly addresses target classes, signalling pathways and cellular processes. Classify drugs by comparison to an extensive compound database defining MOA and predicting safety threats.

It features: analysis of drug activity for any target class or pathway across cellular systems; high-content/high-throughput data capture and analysis; in-depth data interpretation including comparison to an extensive database of known drugs and toxicants; improved decision making throughout the development process.

Suitable applications include: target validation, HTS, SAR testing, toxicity and drug safety screens and compound selectivity testing.

Online: www.lonza.com
Phone: 03 9550 0883
Related Products

BioGX Xfree COVID-19 Direct RT-PCR test

The Xfree COVID-19 Direct RT-PCR test is a complete test in a single vial, lyophilised...

Bio-Rad Laboratories CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems

Bio-Rad Laboratories' CFX Opus 96 and CFX Opus 384 Real-Time PCR Systems are suitable for...

PCR Biosystems NGSBIO Library Quant Kit for Illumina

The kit contains all the components necessary for sensitive quantification of DNA libraries prior...

  • All content Copyright © 2020 Westwick-Farrow Pty Ltd